Considerations for Shared Decision Management in PUPs
Read the Astermark et al. Ther Adv Hematol 2023 publication
For previously untreated patients with haemophilia A or B, treatment choices are expanding while evidence remains limited. This review explores shared decision-making in early life, the central role of primary prophylaxis and the value of multidisciplinary discussions with families – covering bleed recognition, inhibitor risk and evolving therapies – to support personalized, optimal care.
Abbreviations
PUP, Previously untreated patient
What to read next
-
Updated
Outstanding Challenges in Haemophilia B Research
Astermark et al. Ther Adv Hematol 2026
-
Updated
Non-severe Haemohilia: Renewed Focus and Outcomes
Dolan et al. Semin Thromb Hemost 2025
-
Updated
Future Needs for Innovation in Haemophilia
Blatny et al. Ther Adv Hematol 2024
-
Updated
Teenagers and Adolescents With Haemophilia
Konigs et al. J Clin Med 2024
-
Updated
Synovitis and Joint Health in Patients With Haemophilia
Mancuso et al. Haemophilia 2023
-
Updated
Shared Decision Management in PUPs With Haemophilia
Astermark et al. Ther Adv Hematol 2023
-
Updated
Revised Classification of FVIII Concentrates
Hermans, et al. Blood Adv 2026
-
Updated
How Much Prophylaxis is Enough in Haemophilia?
Carcao et al. Haemophilia 2024
-
Updated
Targeting Higher FVIII Levels: a Narrative Review
Read the Malec et al. Haemophilia 2023 publication
-
Updated
Towards Achieving a Haemophilia-free Mind
Hermans et al. Haemophilia 2023